Vinblastine
Research News and Information

Sunday, November 22, 2009

Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.

13 Dec 2009 Children with Down syndrome (DS) are at increased risk for the development of acute leukemia but they rarely develop other hematologic malignancies or solid tumors. Despite aggressive supportive care, DS patients have increased risk of treatment ... Read more...

Natural history and outcome of optic pathway gliomas in children.

13 Dec 2009 BACKGROUND: The optimal management of optic pathway gliomas (OPGs) is complicated by their variable natural history, the association with neurofibromatosis type 1 (NF1) and difficulties in defining progression and response to treatment. METHODS: ... Read more...

Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant.

30 Oct 2009 Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has clinicopathologic, immunophenotypic, and molecular features that are distinct from classical Hodgkin lymphoma (cHL). Distinguishing these entities is usually straightforward, but unusual ... Read more...

Latest indexed articles for 'Vinblastine'

These are the very latest articles for this heading:

• Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma. 13 Dec 2009
• Natural history and outcome of optic pathway gliomas in children. 13 Dec 2009
• Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant. 30 Oct 2009
• Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. 29 Sep 2009
• Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug. 13 Sep 2009
• Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. 13 Sep 2009
• Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. 13 Sep 2009
• Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies. Sep 2009
• Second-line therapy in bladder cancer. 30 Aug 2009
• Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC. 30 Aug 2009
• [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab] 30 Aug 2009
• Evaluation of the flavonoid oroxylin A as an inhibitor of P-glycoprotein-mediated cellular efflux. 30 Aug 2009
• Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. 29 Aug 2009
• Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. 23 Aug 2009
• Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. 22 Aug 2009
• Influence of melanosome dynamics on melanoma drug sensitivity. 22 Aug 2009
• Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. 15 Aug 2009
• Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. 8 Aug 2009
• Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits. 4 Aug 2009
• International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. 3 Aug 2009

See a longer list of these articles.

Technical information about 'Vinblastine'

Definition: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Registry Number: 865-21-4

Descriptor UI: D014747

Alternative terms: Vinblastine; Vincaleukoblastine; Gastrozepin Brand of Vinblastine Sulfate; Faulding Brand of Vinblastine Sulfate; Vinblastinsulfat-Gry; Gry Brand of Vinblastine Sulfate; Velban; Vinblastina Lilly; Velbe; EG Labo Brand of Vinblastine Sulfate; Lilly Brand of Vinblastine Sulfate; Vinblastin Hexal; Hexal Brand of Vinblastine Sulfate; Vinblastine Sulfate; Sulfate, Vinblastine; cellblastin; cell pharm Brand of Vinblastine Sulfate; Lemblastine; Lemery Brand of Vinblastine Sulfate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; biosynthesis;

Pharmacological Action: Antineoplastic Agents, Phytogenic; Tubulin Modulators;

Tree Number: D03.132.436.681.827.650; D03.438.473.402.681.827.650;

Technical Notes: /biosyn permitted if by plant